Scharfenort Monica, Hernström Veronica, Rosqvist Kristina, Ljung Hanna, Nilsson Maria H, Odin Per
Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden.
Department of Neurology, Rehabilitation Medicine, Memory and Geriatrics, Skåne University Hospital, Lund, Sweden.
Parkinsons Dis. 2025 Jul 25;2025:6681692. doi: 10.1155/padi/6681692. eCollection 2025.
It is unclear whether the two device-aided therapies (DATs: deep brain stimulation [DBS] and levodopa-carbidopa intestinal gel [LCIG]) affect personality in patients with Parkinson's disease (PD). This retrospective study aims to explore if patients with PD and their close relatives experience any changes in the patient's personality following the start of DAT. In total, 32 patients with DAT (17 DBS and 15 levodopa pump-based therapy) and their close relatives ( = 32) were asked to retrospectively assess potential personality changes in the patients using the Big Five Inventory (BFI) following DAT. They also answered questions regarding perceived quality of life and perceived impact on motor symptoms. There was a diverse perceived change in the patients' five personality traits when divided into the type of therapy. DBS patients reported decreased extraversion (70.6%, = 12), while their close relatives reported an increase in the trait neuroticism (82.4%, = 14). A significant difference was found in perceived changes in agreeableness, with 8 DBS patients reporting an increase and 4 close relatives reporting a decrease (=0.008). Most of the pump patients (LCIG) reported a decreased conscientiousness (66.7% = 10), a perception confirmed by 73.3% ( = 11) of their close relatives, who in addition reported an increase in neuroticism (73.3%, = 11). This study suggests perceived personality changes following DAT (DBS or LCIG), which vary by therapy and respondent role. Larger studies are needed, but the findings signal the importance of considering both patients' and their relatives' perspectives when assessing personality changes.
目前尚不清楚两种器械辅助疗法（DATs：深部脑刺激 [DBS] 和左旋多巴 - 卡比多巴肠凝胶 [LCIG]）是否会影响帕金森病（PD）患者的人格。这项回顾性研究旨在探讨帕金森病患者及其近亲在开始接受DAT治疗后，患者的人格是否有任何变化。总共32名接受DAT治疗的患者（17名接受DBS治疗，15名接受基于左旋多巴泵的治疗）及其近亲（n = 32）被要求使用大五人格量表（BFI）回顾性评估患者在接受DAT治疗后的潜在人格变化。他们还回答了有关生活质量感知和对运动症状影响感知的问题。根据治疗类型划分，患者的五种人格特质存在不同的感知变化。接受DBS治疗的患者报告外向性降低（70.6%，n = 12），而他们的近亲报告神经质特质增加（82.4%，n = 14）。在宜人性的感知变化方面发现了显著差异，8名接受DBS治疗的患者报告增加，4名近亲报告减少（P = 0.008）。大多数接受泵治疗的患者（LCIG）报告尽责性降低（66.7%，n = 10），73.3%（n = 11）的近亲也证实了这一点，他们还报告神经质增加（73.3%，n = 11）。这项研究表明，接受DAT（DBS或LCIG）治疗后存在人格感知变化，且因治疗方式和受访者角色而异。需要进行更大规模的研究，但研究结果表明，在评估人格变化时考虑患者及其亲属的观点很重要。
